NDA 20181, held by Hospira. Soybean Oil.
As of Nov 13, 2026, NDA 20181 (Liposyn Iii 30%), held by Hospira, was first approved by FDA on Jan 13, 1998, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 13, 1998 | Original applicationNew dosage form · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Liposyn Iii 30%30% · injectable;injection | Soybean Oil | Discontinued |
| Mar 12, 2003 | Supplement 1Manufacturing · Standard review | Approved | |
| Jan 13, 1998 | Original applicationNew dosage form · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
